The estimated Net Worth of James B Weissman is at least $2.28 millió dollars as of 15 December 2021. Mr. Weissman owns over 3,775 units of Dicerna Pharmaceuticals Inc stock worth over $755,801 and over the last 11 years he sold DRNA stock worth over $801,936. In addition, he makes $724,572 as Chief Operating Officer és Executive Vice President at Dicerna Pharmaceuticals Inc.
James has made over 33 trades of the Dicerna Pharmaceuticals Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 3,775 units of DRNA stock worth $144,281 on 15 December 2021.
The largest trade he's ever made was exercising 40,000 units of Dicerna Pharmaceuticals Inc stock on 18 November 2019 worth over $136,800. On average, James trades about 7,379 units every 70 days since 2013. As of 15 December 2021 he still owns at least 19,775 units of Dicerna Pharmaceuticals Inc stock.
You can see the complete history of Mr. Weissman stock trades at the bottom of the page.
James B. Weissman serves as Chief Operating Officer, Executive Vice President of the Company. He has more than 30 years’ experience in the life sciences industry, with extensive international management experience in biotech and pharmaceutical general management, product development, licensing, business development, marketing, and merger and acquisition activities. Mr. Weissman serves on the board of Receptor Holdings, Inc. Prior to Dicerna, Mr. Weissman was Vice President of Business Development at MannKind Corporation, responsible for leading the company’s activities relating to licensing, new products, and strategic planning. Prior to MannKind, Mr. Weissman held leadership positions in both business development and marketing at Pfizer Pharmaceuticals, Inc. in Tokyo, most recently as Senior Director of Marketing. In that position, he was responsible for the sales, profit, and strategic targets for the company’s specialty products, including central nervous system (CNS) endocrinology, ophthalmology and oncology therapeutics, and diversified portfolios. Mr. Weissman holds a Bachelor of Science degree from Bates College.
As the Chief Operating Officer és Executive Vice President of Dicerna Pharmaceuticals Inc, the total compensation of James Weissman at Dicerna Pharmaceuticals Inc is $724,572. There are 3 executives at Dicerna Pharmaceuticals Inc getting paid more, with Douglas Fambrough having the highest compensation of $5,048,130.
James Weissman is 58, he's been the Chief Operating Officer és Executive Vice President of Dicerna Pharmaceuticals Inc since 2019. There are 5 older and 7 younger executives at Dicerna Pharmaceuticals Inc. The oldest executive at Dicerna Pharmaceuticals Inc is Patrick Gray, 71, who is the Independent Director.
James's mailing address filed with the SEC is C/O TELESIS BIO INC., 10431 WATERIDGE CIRCLE, SUITE 150, SAN DIEGO, CA, 92121.
Over the last 11 years, insiders at Dicerna Pharmaceuticals Inc have traded over $233,644,011 worth of Dicerna Pharmaceuticals Inc stock and bought 2,456,100 units worth $36,501,331 . The most active insiders traders include Capital Management, Llc Kol..., Nicole Vitullo és Peter Kolchinsky. On average, Dicerna Pharmaceuticals Inc executives and independent directors trade stock every 21 days with the average trade being worth of $4,025,674. The most recent stock trade was executed by Douglas W. Pagan on 15 December 2021, trading 2,050 units of DRNA stock currently worth $78,351.
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease. Using its proprietary GalXC™ and GalXC-Plus™ RNAi technologies, Dicerna is committed to developing RNAi-based therapies with the potential to treat both rare and more prevalent diseases. By silencing disease-causing genes, Dicerna's GalXC platform has the potential to address conditions that are difficult to treat with other modalities. Initially focused on disease-causing genes in the liver, Dicerna has continued to innovate and is exploring new applications of its RNAi technology with GalXC-Plus, which expands on the functionality and application of its flagship liver-based GalXC technology, and has the potential to treat diseases across multiple therapeutic areas. In addition to its own pipeline of core discovery and clinical candidates, Dicerna has established collaborative relationships with some of the world's leading pharmaceutical companies, including Novo Nordisk A/S, Roche, Eli Lilly and Company, Alexion Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH and Alnylam Pharmaceuticals, Inc. Between Dicerna and its collaborative partners, they currently have more than 20 active discovery, preclinical or clinical programs focused on rare, cardiometabolic, viral, chronic liver and complement-mediated diseases, as well as neurodegenerative diseases and pain. Dicerna's mission is to interfere - to silence genes, to fight disease, to restore health.
Dicerna Pharmaceuticals Inc executives and other stock owners filed with the SEC include: